Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

L’Oreal Settles With FTC Over Gene-Related Anti-Aging Skin Care Claims

This article was originally published in The Tan Sheet

Executive Summary

A proposed consent agreement with FTC bars L’Oreal USA from claiming its Lancome and L’Oreal Paris skin-care products target users’ genes with anti-aging benefits. The settlement, subject to public comment and final FTC approval, follows a 2012 FDA warning that cited some of the same marketing claims.

You may also be interested in...



Class-Actions Increasing As Fallout From Regulatory Action

Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics. Speakers provided examples and tips for staying out of court.

FDA Warns Lancome For Gene/Stem-Cell Claims: A Signal To Marketplace?

Claims for L’Oreal’s Lancome brand’s Genifique anti-aging line identify the products as drugs, FDA says. The agency cites claims that the brand’s technology “boosts the activity of genes” and “has been shown to improve the condition” around stem cells – language not unique in the anti-aging cosmeceutical market.

Federal Court Stays Class Action Against CBD Firm Green Roads To Await FDA Rulemaking

Plaintiffs against Florida-based Green Roads used certificates of analysis the company makes freely available to consumers to determine that batches of two of the company’s products contained “significantly” less cannabidiol versus labeled amounts. A Florida federal court rejected the firm’s motion to dismiss, but it is interested in seeing how FDA rulemaking develops.

Topics

Related Companies

UsernamePublicRestriction

Register

PS107011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel